Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials
Identifieur interne : 000493 ( Canada/Analysis ); précédent : 000492; suivant : 000494Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials
Auteurs : Susan Manzi [États-Unis] ; Jorge Sánchez-Guerrero [Mexique] ; Joan T. Merrill [États-Unis] ; Richard Furie [États-Unis] ; Dafna Gladman [Canada] ; Sandra V. Navarra [Philippines] ; Ellen M. Ginzler [États-Unis] ; David P. D'Cruz [Royaume-Uni] ; Andrea Doria [Italie] ; Simon Cooper [États-Unis] ; Z John Zhong [États-Unis] ; Douglas Hough [États-Unis] ; William Freimuth [États-Unis] ; Michelle A. Petri [États-Unis]Source :
- Annals of the Rheumatic Diseases [ 0003-4967 ] ; 2012-11.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
- Activity index, Arthritis rheum, B-Lymphocyte, Baseline, Belimumab, Belimumab groups, Belimumab treatment, Bilag, Board membership, British isles lupus assessment group, Chemotherapy, Consulting fees, Data acquisition, Disease activity, Disease characteristics, Domain, Domain score, Epidemiological research, Erythematosus, Fewer patients, Grant support, Gure, Haematological, Human, Immunological, Immunological domain, Immunomodulator, Improvement rates, Lupus, Lupus erythematosus disease activity index, Lymphocyte, Lymphocyte stimulator, More organ systems, More patients, Mucocutaneous, Multiple, Musculoskeletal, Musculoskeletal domain, Organ, Organ domain involvement, Organ domain scores, Organ domains, Organ systems, Phase III trial, Placebo, Primary endpoint, Renal, Response rates, Rheum, Rheumatology, Standard therapy, Systemic lupus erythematosus, Treatment effect, Treatment groups, Vasculitis.
- Teeft :
- Arthritis rheum, Baseline, Belimumab, Belimumab groups, Belimumab treatment, Bilag, Board membership, British isles lupus assessment group, Consulting fees, Data acquisition, Disease activity, Disease characteristics, Domain, Domain score, Epidemiological research, Erythematosus, Fewer patients, Grant support, Gure, Haematological, Immunological, Immunological domain, Improvement rates, Lupus, Lupus erythematosus disease activity index, Lymphocyte, Lymphocyte stimulator, More organ systems, More patients, Mucocutaneous, Musculoskeletal, Musculoskeletal domain, Organ, Organ domain involvement, Organ domain scores, Organ domains, Organ systems, Placebo, Primary endpoint, Renal, Response rates, Rheum, Standard therapy, Systemic lupus erythematosus, Treatment effect, Treatment groups, Vasculitis.
Abstract
Objective To evaluate the effects of belimumab versus placebo, plus standard systemic lupus erythematosus (SLE) therapy, on organ domain-specific SLE disease activity. Methods Data obtained after 52 weeks of treatment from two phase III trials (BLISS-52 and BLISS-76) comparing belimumab 1 and 10 mg/kg versus placebo, plus standard therapy, in 1684 autoantibody-positive patients were analysed post hoc for changes in British Isles Lupus Assessment Group (BILAG) and Safety of Estrogens in Lupus National Assessment–Systemic Lupus Erythematosus Disease Activity Index (SELENA–SLEDAI) organ domain scores. Results At baseline, the domains involved in the majority of patients were musculoskeletal and mucocutaneous by both BILAG and SELENA–SLEDAI, and immunological by SELENA–SLEDAI. At 52 weeks, significantly more patients treated with belimumab versus placebo had improvement in BILAG musculoskeletal and mucocutaneous domains (1 and 10 mg/kg), and in SELENA–SLEDAI mucocutaneous (10 mg/kg), musculoskeletal (1 mg/kg) and immunological (1 and 10 mg/kg) domains. Improvement was also observed in other organ systems with a low prevalence (≤16%) at baseline, including the SELENA–SLEDAI vasculitis and central nervous system domains. Significantly fewer patients treated with belimumab versus placebo had worsening in the BILAG haematological domain (1 mg/kg) and in the SELENA–SLEDAI immunological (10 mg/kg), haematological (10 mg/kg) and renal (1 mg/kg) domains. Conclusions Belimumab treatment improved overall SLE disease activity in the most common musculoskeletal and mucocutaneous organ domains. Less worsening occurred in the haematological, immunological and renal domains.
Url:
DOI: 10.1136/annrheumdis-2011-200831
Affiliations:
- Canada, Italie, Mexique, Philippines, Royaume-Uni, États-Unis
- Angleterre, Grand Londres, Maryland, Oklahoma, Pennsylvanie, État de New York
- Londres
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000204
- to stream Istex, to step Curation: 000204
- to stream Istex, to step Checkpoint: 001109
- to stream Main, to step Merge: 007C44
- to stream PascalFrancis, to step Corpus: 003571
- to stream PascalFrancis, to step Curation: 001956
- to stream PascalFrancis, to step Checkpoint: 003730
- to stream Main, to step Merge: 009A16
- to stream Main, to step Curation: 007767
- to stream Main, to step Exploration: 007767
- to stream Canada, to step Extraction: 000493
Links to Exploration step
ISTEX:0944527FEB9B49F85DEDD372DFE3B676C0CB1C22Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials</title><author><name sortKey="Manzi, Susan" sort="Manzi, Susan" uniqKey="Manzi S" first="Susan" last="Manzi">Susan Manzi</name></author><author><name sortKey="Sanchez Guerrero, Jorge" sort="Sanchez Guerrero, Jorge" uniqKey="Sanchez Guerrero J" first="Jorge" last="Sánchez-Guerrero">Jorge Sánchez-Guerrero</name></author><author><name sortKey="Merrill, Joan T" sort="Merrill, Joan T" uniqKey="Merrill J" first="Joan T" last="Merrill">Joan T. Merrill</name></author><author><name sortKey="Furie, Richard" sort="Furie, Richard" uniqKey="Furie R" first="Richard" last="Furie">Richard Furie</name></author><author><name sortKey="Gladman, Dafna" sort="Gladman, Dafna" uniqKey="Gladman D" first="Dafna" last="Gladman">Dafna Gladman</name></author><author><name sortKey="Navarra, Sandra V" sort="Navarra, Sandra V" uniqKey="Navarra S" first="Sandra V" last="Navarra">Sandra V. Navarra</name></author><author><name sortKey="Ginzler, Ellen M" sort="Ginzler, Ellen M" uniqKey="Ginzler E" first="Ellen M" last="Ginzler">Ellen M. Ginzler</name></author><author><name sortKey="D Cruz, David P" sort="D Cruz, David P" uniqKey="D Cruz D" first="David P" last="D'Cruz">David P. D'Cruz</name></author><author><name sortKey="Doria, Andrea" sort="Doria, Andrea" uniqKey="Doria A" first="Andrea" last="Doria">Andrea Doria</name></author><author><name sortKey="Cooper, Simon" sort="Cooper, Simon" uniqKey="Cooper S" first="Simon" last="Cooper">Simon Cooper</name></author><author><name sortKey="Zhong, Z John" sort="Zhong, Z John" uniqKey="Zhong Z" first="Z John" last="Zhong">Z John Zhong</name></author><author><name sortKey="Hough, Douglas" sort="Hough, Douglas" uniqKey="Hough D" first="Douglas" last="Hough">Douglas Hough</name></author><author><name sortKey="Freimuth, William" sort="Freimuth, William" uniqKey="Freimuth W" first="William" last="Freimuth">William Freimuth</name></author><author><name sortKey="Petri, Michelle A" sort="Petri, Michelle A" uniqKey="Petri M" first="Michelle A" last="Petri">Michelle A. Petri</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:0944527FEB9B49F85DEDD372DFE3B676C0CB1C22</idno><date when="2012" year="2012">2012</date><idno type="doi">10.1136/annrheumdis-2011-200831</idno><idno type="url">https://api.istex.fr/document/0944527FEB9B49F85DEDD372DFE3B676C0CB1C22/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000204</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000204</idno><idno type="wicri:Area/Istex/Curation">000204</idno><idno type="wicri:Area/Istex/Checkpoint">001109</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001109</idno><idno type="wicri:doubleKey">0003-4967:2012:Manzi S:effects:of:belimumab</idno><idno type="wicri:Area/Main/Merge">007C44</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:12-0413254</idno><idno type="wicri:Area/PascalFrancis/Corpus">003571</idno><idno type="wicri:Area/PascalFrancis/Curation">001956</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">003730</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">003730</idno><idno type="wicri:doubleKey">0003-4967:2012:Manzi S:effects:of:belimumab</idno><idno type="wicri:Area/Main/Merge">009A16</idno><idno type="wicri:Area/Main/Curation">007767</idno><idno type="wicri:Area/Main/Exploration">007767</idno><idno type="wicri:Area/Canada/Extraction">000493</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials</title><author><name sortKey="Manzi, Susan" sort="Manzi, Susan" uniqKey="Manzi S" first="Susan" last="Manzi">Susan Manzi</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Allegheny Singer Research Institute, West Penn Allegheny Health System, Temple University School of Medicine, Pittsburgh, Pennsylvania</wicri:regionArea><placeName><region type="state">Pennsylvanie</region></placeName></affiliation></author><author><name sortKey="Sanchez Guerrero, Jorge" sort="Sanchez Guerrero, Jorge" uniqKey="Sanchez Guerrero J" first="Jorge" last="Sánchez-Guerrero">Jorge Sánchez-Guerrero</name><affiliation wicri:level="1"><country xml:lang="fr">Mexique</country><wicri:regionArea>Instituto Nacional de Ciencias Medicas y Nutricion “Salvador Zubiran,” Delegacion Tlalpan, Mexico City</wicri:regionArea><wicri:noRegion>Mexico City</wicri:noRegion></affiliation></author><author><name sortKey="Merrill, Joan T" sort="Merrill, Joan T" uniqKey="Merrill J" first="Joan T" last="Merrill">Joan T. Merrill</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma</wicri:regionArea><placeName><region type="state">Oklahoma</region></placeName></affiliation></author><author><name sortKey="Furie, Richard" sort="Furie, Richard" uniqKey="Furie R" first="Richard" last="Furie">Richard Furie</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>North Shore–LIJ Health System, Lake Success, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Gladman, Dafna" sort="Gladman, Dafna" uniqKey="Gladman D" first="Dafna" last="Gladman">Dafna Gladman</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Toronto Western Hospital, Toronto</wicri:regionArea><wicri:noRegion>Toronto</wicri:noRegion></affiliation></author><author><name sortKey="Navarra, Sandra V" sort="Navarra, Sandra V" uniqKey="Navarra S" first="Sandra V" last="Navarra">Sandra V. Navarra</name><affiliation wicri:level="1"><country xml:lang="fr">Philippines</country><wicri:regionArea>University of Santo Tomas Hospital, Manila</wicri:regionArea><wicri:noRegion>Manila</wicri:noRegion></affiliation></author><author><name sortKey="Ginzler, Ellen M" sort="Ginzler, Ellen M" uniqKey="Ginzler E" first="Ellen M" last="Ginzler">Ellen M. Ginzler</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>SUNY Downstate Medical Center, Brooklyn, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="D Cruz, David P" sort="D Cruz, David P" uniqKey="D Cruz D" first="David P" last="D'Cruz">David P. D'Cruz</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>St Thomas' Hospital, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Doria, Andrea" sort="Doria, Andrea" uniqKey="Doria A" first="Andrea" last="Doria">Andrea Doria</name><affiliation wicri:level="1"><country xml:lang="fr">Italie</country><wicri:regionArea>University of Padova, Padova</wicri:regionArea><wicri:noRegion>Padova</wicri:noRegion></affiliation></author><author><name sortKey="Cooper, Simon" sort="Cooper, Simon" uniqKey="Cooper S" first="Simon" last="Cooper">Simon Cooper</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Human Genome Sciences, Rockville, Maryland</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Zhong, Z John" sort="Zhong, Z John" uniqKey="Zhong Z" first="Z John" last="Zhong">Z John Zhong</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Human Genome Sciences, Rockville, Maryland</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Hough, Douglas" sort="Hough, Douglas" uniqKey="Hough D" first="Douglas" last="Hough">Douglas Hough</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Human Genome Sciences, Rockville, Maryland</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Freimuth, William" sort="Freimuth, William" uniqKey="Freimuth W" first="William" last="Freimuth">William Freimuth</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Human Genome Sciences, Rockville, Maryland</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Petri, Michelle A" sort="Petri, Michelle A" uniqKey="Petri M" first="Michelle A" last="Petri">Michelle A. Petri</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Johns Hopkins University, School of Medicine, Baltimore, Maryland</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Annals of the Rheumatic Diseases</title><title level="j" type="abbrev">Ann Rheum Dis</title><idno type="ISSN">0003-4967</idno><idno type="eISSN">1468-2060</idno><imprint><publisher>BMJ Publishing Group Ltd and European League Against Rheumatism</publisher><date type="published" when="2012-11">2012-11</date><biblScope unit="volume">71</biblScope><biblScope unit="issue">11</biblScope><biblScope unit="page" from="1833">1833</biblScope></imprint><idno type="ISSN">0003-4967</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0003-4967</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Activity index</term><term>Arthritis rheum</term><term>B-Lymphocyte</term><term>Baseline</term><term>Belimumab</term><term>Belimumab groups</term><term>Belimumab treatment</term><term>Bilag</term><term>Board membership</term><term>British isles lupus assessment group</term><term>Chemotherapy</term><term>Consulting fees</term><term>Data acquisition</term><term>Disease activity</term><term>Disease characteristics</term><term>Domain</term><term>Domain score</term><term>Epidemiological research</term><term>Erythematosus</term><term>Fewer patients</term><term>Grant support</term><term>Gure</term><term>Haematological</term><term>Human</term><term>Immunological</term><term>Immunological domain</term><term>Immunomodulator</term><term>Improvement rates</term><term>Lupus</term><term>Lupus erythematosus disease activity index</term><term>Lymphocyte</term><term>Lymphocyte stimulator</term><term>More organ systems</term><term>More patients</term><term>Mucocutaneous</term><term>Multiple</term><term>Musculoskeletal</term><term>Musculoskeletal domain</term><term>Organ</term><term>Organ domain involvement</term><term>Organ domain scores</term><term>Organ domains</term><term>Organ systems</term><term>Phase III trial</term><term>Placebo</term><term>Primary endpoint</term><term>Renal</term><term>Response rates</term><term>Rheum</term><term>Rheumatology</term><term>Standard therapy</term><term>Systemic lupus erythematosus</term><term>Treatment effect</term><term>Treatment groups</term><term>Vasculitis</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Bélimumab</term><term>Chimiothérapie</term><term>Essai clinique phase III</term><term>Homme</term><term>Immunomodulateur</term><term>Indice d'activité</term><term>Lupus érythémateux disséminé</term><term>Lymphocyte B</term><term>Multiple</term><term>Organe</term><term>Rhumatologie</term></keywords><keywords scheme="Teeft" xml:lang="en"><term>Arthritis rheum</term><term>Baseline</term><term>Belimumab</term><term>Belimumab groups</term><term>Belimumab treatment</term><term>Bilag</term><term>Board membership</term><term>British isles lupus assessment group</term><term>Consulting fees</term><term>Data acquisition</term><term>Disease activity</term><term>Disease characteristics</term><term>Domain</term><term>Domain score</term><term>Epidemiological research</term><term>Erythematosus</term><term>Fewer patients</term><term>Grant support</term><term>Gure</term><term>Haematological</term><term>Immunological</term><term>Immunological domain</term><term>Improvement rates</term><term>Lupus</term><term>Lupus erythematosus disease activity index</term><term>Lymphocyte</term><term>Lymphocyte stimulator</term><term>More organ systems</term><term>More patients</term><term>Mucocutaneous</term><term>Musculoskeletal</term><term>Musculoskeletal domain</term><term>Organ</term><term>Organ domain involvement</term><term>Organ domain scores</term><term>Organ domains</term><term>Organ systems</term><term>Placebo</term><term>Primary endpoint</term><term>Renal</term><term>Response rates</term><term>Rheum</term><term>Standard therapy</term><term>Systemic lupus erythematosus</term><term>Treatment effect</term><term>Treatment groups</term><term>Vasculitis</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract">Objective To evaluate the effects of belimumab versus placebo, plus standard systemic lupus erythematosus (SLE) therapy, on organ domain-specific SLE disease activity. Methods Data obtained after 52 weeks of treatment from two phase III trials (BLISS-52 and BLISS-76) comparing belimumab 1 and 10 mg/kg versus placebo, plus standard therapy, in 1684 autoantibody-positive patients were analysed post hoc for changes in British Isles Lupus Assessment Group (BILAG) and Safety of Estrogens in Lupus National Assessment–Systemic Lupus Erythematosus Disease Activity Index (SELENA–SLEDAI) organ domain scores. Results At baseline, the domains involved in the majority of patients were musculoskeletal and mucocutaneous by both BILAG and SELENA–SLEDAI, and immunological by SELENA–SLEDAI. At 52 weeks, significantly more patients treated with belimumab versus placebo had improvement in BILAG musculoskeletal and mucocutaneous domains (1 and 10 mg/kg), and in SELENA–SLEDAI mucocutaneous (10 mg/kg), musculoskeletal (1 mg/kg) and immunological (1 and 10 mg/kg) domains. Improvement was also observed in other organ systems with a low prevalence (≤16%) at baseline, including the SELENA–SLEDAI vasculitis and central nervous system domains. Significantly fewer patients treated with belimumab versus placebo had worsening in the BILAG haematological domain (1 mg/kg) and in the SELENA–SLEDAI immunological (10 mg/kg), haematological (10 mg/kg) and renal (1 mg/kg) domains. Conclusions Belimumab treatment improved overall SLE disease activity in the most common musculoskeletal and mucocutaneous organ domains. Less worsening occurred in the haematological, immunological and renal domains.</div></front></TEI><affiliations><list><country><li>Canada</li><li>Italie</li><li>Mexique</li><li>Philippines</li><li>Royaume-Uni</li><li>États-Unis</li></country><region><li>Angleterre</li><li>Grand Londres</li><li>Maryland</li><li>Oklahoma</li><li>Pennsylvanie</li><li>État de New York</li></region><settlement><li>Londres</li></settlement></list><tree><country name="États-Unis"><region name="Pennsylvanie"><name sortKey="Manzi, Susan" sort="Manzi, Susan" uniqKey="Manzi S" first="Susan" last="Manzi">Susan Manzi</name></region><name sortKey="Cooper, Simon" sort="Cooper, Simon" uniqKey="Cooper S" first="Simon" last="Cooper">Simon Cooper</name><name sortKey="Freimuth, William" sort="Freimuth, William" uniqKey="Freimuth W" first="William" last="Freimuth">William Freimuth</name><name sortKey="Furie, Richard" sort="Furie, Richard" uniqKey="Furie R" first="Richard" last="Furie">Richard Furie</name><name sortKey="Ginzler, Ellen M" sort="Ginzler, Ellen M" uniqKey="Ginzler E" first="Ellen M" last="Ginzler">Ellen M. Ginzler</name><name sortKey="Hough, Douglas" sort="Hough, Douglas" uniqKey="Hough D" first="Douglas" last="Hough">Douglas Hough</name><name sortKey="Merrill, Joan T" sort="Merrill, Joan T" uniqKey="Merrill J" first="Joan T" last="Merrill">Joan T. Merrill</name><name sortKey="Petri, Michelle A" sort="Petri, Michelle A" uniqKey="Petri M" first="Michelle A" last="Petri">Michelle A. Petri</name><name sortKey="Zhong, Z John" sort="Zhong, Z John" uniqKey="Zhong Z" first="Z John" last="Zhong">Z John Zhong</name></country><country name="Mexique"><noRegion><name sortKey="Sanchez Guerrero, Jorge" sort="Sanchez Guerrero, Jorge" uniqKey="Sanchez Guerrero J" first="Jorge" last="Sánchez-Guerrero">Jorge Sánchez-Guerrero</name></noRegion></country><country name="Canada"><noRegion><name sortKey="Gladman, Dafna" sort="Gladman, Dafna" uniqKey="Gladman D" first="Dafna" last="Gladman">Dafna Gladman</name></noRegion></country><country name="Philippines"><noRegion><name sortKey="Navarra, Sandra V" sort="Navarra, Sandra V" uniqKey="Navarra S" first="Sandra V" last="Navarra">Sandra V. Navarra</name></noRegion></country><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="D Cruz, David P" sort="D Cruz, David P" uniqKey="D Cruz D" first="David P" last="D'Cruz">David P. D'Cruz</name></region></country><country name="Italie"><noRegion><name sortKey="Doria, Andrea" sort="Doria, Andrea" uniqKey="Doria A" first="Andrea" last="Doria">Andrea Doria</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Amérique/explor/PittsburghV1/Data/Canada/Analysis
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000493 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Canada/Analysis/biblio.hfd -nk 000493 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Amérique
|area= PittsburghV1
|flux= Canada
|étape= Analysis
|type= RBID
|clé= ISTEX:0944527FEB9B49F85DEDD372DFE3B676C0CB1C22
|texte= Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials
}}
| This area was generated with Dilib version V0.6.38. |  |